You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

CLINICAL TRIALS PROFILE FOR XYNTHA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for XYNTHA

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01051544 ↗	Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive	Withdrawn	Biotest Pharmaceuticals Corporation	N/A	2009-09-25	This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.
NCT01051544 ↗	Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive	Withdrawn	Charta Fondazione	N/A	2009-09-25	This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.
NCT01051544 ↗	Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive	Withdrawn	Charta Foundation	N/A	2009-09-25	This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.
NCT01051544 ↗	Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive	Withdrawn	CSL Behring	N/A	2009-09-25	This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.
NCT01051544 ↗	Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive	Withdrawn	Grifols Biologicals Inc.	N/A	2009-09-25	This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for XYNTHA

Condition Name

Chart
Table

Condition Name for XYNTHA
Intervention	Trials
Hemophilia A	4
Severe Hemophilia A	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for XYNTHA
Intervention	Trials
Hemophilia A	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for XYNTHA

Trials by Country

Map
Table

Trials by Country for XYNTHA
Location	Trials
China	16
Korea, Republic of	2
United States	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for XYNTHA
Location	Trials
California	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for XYNTHA

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for XYNTHA
Clinical Trial Phase	Trials
Phase 4	1
Phase 1	2
N/A	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for XYNTHA
Clinical Trial Phase	Trials
Completed	3
Withdrawn	1
Unknown status	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for XYNTHA

Sponsor Name

Chart
Table

Sponsor Name for XYNTHA
Sponsor	Trials
Pfizer	3
Biotest Pharmaceuticals Corporation	1
Charta Fondazione	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for XYNTHA
Sponsor	Trials
Industry	10
Other	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.